OVERVIEW

Mitigating Disease Burden and Healthcare Disparities in Relapsed/Refractory Multiple Myeloma: A Multidisciplinary Task Force Podcast is organized by i3 Health.

Dates Available:
September 11, 2024 - September 10, 2025

Statement of Need:
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractory multiple myeloma; however, many patients face barriers to timely and appropriate treatment, including racial, ethnic, and socioeconomic disparities in health care delivery and services. While Black patients with multiple myeloma are more likely to have a lower-risk genetic profile, multiple myeloma remains twice as deadly in Black patients compared with White patients. Both Black and Hispanic patients experience a longer time from diagnosis to novel therapy initiation compared with non-Hispanic White patients, and they are also less likely to receive autologous stem cell transplant. Additionally, Black and Hispanic patients, as well as patients who are older or live in rural areas, are underrepresented in clinical trials of novel therapies, creating a poor reflection of the real-world patient population (Multiple Myeloma Research Foundation, 2023). In order to provide optimal health care delivery, this Multiple Myeloma Task Force podcast will provide a consensus opinion on mitigating disease burden and health care disparities in relapsed/refractory multiple myeloma. It features perspectives from Task Force Co-Chairs: Sikander Ailawadhi, MD, Professor of Medicine at the Mayo Clinic and Rahul Banerjee, MD, FACP, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington.

Learning Objectives:
Upon completion of this activity, participants should be able to

Identify factors that can inform treatment selection for individual patients with RRMM
Explain the clinical significance of measurable residual disease (MRD) negativity in the management of MM
Distinguish current and emerging combination and sequential treatment strategies for MM patients experiencing early relapse and late relapse
Assess interdisciplinary strategies for reducing disparities in MM care

ACCREDITATION & CREDITS

Jointly Accredited Provider
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
i3 Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 9/10/2025. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development
A maximum of 0.5 ANCC contact hours may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.3 ANCC contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, for 0.5 ANCC contact hours.

ONCC Recertification
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 0.5 ILNA points toward:
Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
Oncology Nursing Practice (OCN®)
Psychosocial Dimensions of Care (AOCNP®, CPHON®, OCN®, CBCN®)
Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)
Treatment (OCN®, CBCN®, AOCNP®, CPHON®)
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.

0.5 AMA PRA Category 1 Credit™

0.5 MOC

0.5 CME/Contact Hours

0.5 CEU’s

FACULTY

Sikander Ailawadhi

MDOncology, Hematology Blood and Marrow Transplant

PhD, RN, MSN, APRN-BC, AOCN, FAANNurse Practitioner, Oncology Nursing

Rahul Banerjee

MD, FACP

Shonali Midha

TARGET AUDIENCE

PhysicianNursingPhysician AssistantOncologistsFamily PhysiciansHealthcare ProfessionalsNursesHematologistNurse AssistantsFamily PractitionersNurse PractitionersHealth Care PractitionersGeneral Pediatricians